Stock Market Information | Stock Nod - Stay Connected. Never miss a trade.

FDA Advisory Panel To Review Cell Therapeutics' Pixantrone

Monday February 08, 2010 - 12:29 PM EST

MarketMinute.com Stock News

The Food and Drug Administration will select an advisory panel to review Cell Therapeutics Inc.'s (Nasdaq: CTIC) lymphoma treatment pixantrone due to safety concerns. The stock price plummeted 34 cents to 72 cents.

Related Stocks:

CELL THERAPEUTICS

Print this story

Email this story

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Conference calls info supplied by OpenCompany
Fundamental data supplied by Morningstar
Stock quotes supplied by Telekurs USA

Terms of Service - Privacy Policy

Stocknod.com market data and delayed quotes are powered and implemented by an interactive data solution. All historical stock alerts, chart data, stock picks, quotes, daily updates, company data and news provided by Stocknod stock trading software is provided from provider Financial Content. Stock alerts and stock market analysis is for supplemental stock market analysis and is an automated prospecting tool. Delay times are at least 15 minutes for NASDAQ, 20 minutes for NYSE and Amex. Stocknod.com is sour source for automated stock trading software, stock alerts and stock market analysis. All stock alerts, stock picks, or other stock market analysis information provided "as is" is deemed for informational purposes only, not intended for trading purposes or stock trading advice. Neither StockNod nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance upon information contained herein. By accessing the StockNod site, you agree as a member not to redistribute member stock alerts, stock picks or other stock market analysis or information found therein.